GlassScriptPhysician profile
Mohammad-Ali A El-Harakeh
NPI 1184829061
$5,346.24
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,264 · 2020: $338 · 2021: $794 · 2022: $1,261 · 2023: $1,227 · 2024: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,626 · Education: $63.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.91 |
| Education | $63.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,589.77 | 2019-2024 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,246.81 | 2019-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Mylan Specialty L.P. | $441.38 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $294.73 | 2019-2024 | Dupixent |
| Genzyme Corporation | $287.58 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $272.80 | 2020-2024 | Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.48 | 2019-2024 | |
| United Therapeutics Corporation | $137.10 | 2021-2024 | Tyvaso |
| Novartis Pharmaceuticals Corporation | $88.89 | 2019-2021 | |
| Genentech USA, INC. | $77.10 | 2019-2020 | |
| Harmony Biosciences LLC | $73.11 | 2020-2022 | |
| Shire North American Group INC | $64.54 | 2019 | |
| Insmed, INC. | $60.70 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $57.48 | 2023 | |
| Circassia INC. | $43.90 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $41.37 | 2021-2023 | Smartvest |
| Grifols USA, LLC | $38.69 | 2021-2022 | |
| Intuitive Surgical, INC. | $34.60 | 2020 | |
| Jazz Pharmaceuticals INC. | $32.71 | 2023 | |
| Merck Sharp & Dohme LLC | $31.62 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $31.05 | 2023 | Opsumit, Uptravi |
| Breas Medical, INC. | $29.38 | 2023 | Vivo 45 Ls |
| Avadel Cns Pharmaceuticals, LLC | $25.55 | 2024 | Lumryz |
| Pulmonx Corporation | $22.16 | 2022 | |
| Amgen INC. | $21.80 | 2022 | |
| Baxter Healthcare | $21.50 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Optinose US, INC. | $19.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad-Ali El-Harakeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.